Pasithea Therapeutics Corp Stock Performance
| KTTA Stock | USD 1.25 0.01 0.81% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Pasithea Therapeutics are completely uncorrelated. At this point, Pasithea Therapeutics has a negative expected return of -1.05%. Please make sure to check Pasithea Therapeutics' value at risk, rate of daily change, as well as the relationship between the Rate Of Daily Change and price action indicator , to decide if Pasithea Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Pasithea Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:20 | Last Split Date 2024-01-02 |
1 | Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 | 01/14/2025 |
2 | Acquisition by Steinman Lawrence of 100000 shares of Pasithea Therapeutics subject to Rule 16b-3 | 01/17/2025 |
3 | Pasithea Therapeutics Announces Positive Safety Review Committee Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer | 02/05/2025 |
4 | Discretionary transaction by Abramowitz Israel Maxx of tradable shares of Pasithea Therapeutics subject to Rule 16b-3 | 02/07/2025 |
5 | KTTA stock touches 52-week low at 1.24 amid market challenges - Investing.com India | 02/24/2025 |
6 | Acquisition by Shahinian Eric of 55646 shares of Pasithea Therapeutics at 1.1255 subject to Rule 16b-3 | 03/14/2025 |
7 | Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference | 03/24/2025 |
| Begin Period Cash Flow | 16.3 B |
Pasithea |
Pasithea Therapeutics Relative Risk vs. Return Landscape
If you would invest 279.00 in Pasithea Therapeutics Corp on December 26, 2024 and sell it today you would lose (154.00) from holding Pasithea Therapeutics Corp or give up 55.2% of portfolio value over 90 days. Pasithea Therapeutics Corp is currently does not generate positive expected returns and assumes 7.5831% risk (volatility on return distribution) over the 90 days horizon. In different words, 67% of stocks are less volatile than Pasithea, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pasithea Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pasithea Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pasithea Therapeutics Corp, and traders can use it to determine the average amount a Pasithea Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1391
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KTTA |
Estimated Market Risk
| 7.58 actual daily | 67 67% of assets are less volatile |
Expected Return
| -1.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pasithea Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pasithea Therapeutics by adding Pasithea Therapeutics to a well-diversified portfolio.
Pasithea Therapeutics Fundamentals Growth
Pasithea Stock prices reflect investors' perceptions of the future prospects and financial health of Pasithea Therapeutics, and Pasithea Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pasithea Stock performance.
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | (10.39 M) | ||||
| Shares Outstanding | 1.27 M | ||||
| Price To Book | 0.11 X | ||||
| Price To Sales | 42.15 X | ||||
| Revenue | 486.56 K | ||||
| Gross Profit | (2.21 K) | ||||
| EBITDA | (14.25 B) | ||||
| Net Income | (13.9 B) | ||||
| Cash And Equivalents | 47.94 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 1.28 B | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 51.17 X | ||||
| Book Value Per Share | 17.05 X | ||||
| Cash Flow From Operations | (13.92 B) | ||||
| Earnings Per Share | (12.69) X | ||||
| Market Capitalization | 1.58 M | ||||
| Total Asset | 16.06 B | ||||
| Retained Earnings | (49.58 B) | ||||
| Working Capital | 14.06 M | ||||
About Pasithea Therapeutics Performance
By analyzing Pasithea Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Pasithea Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pasithea Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pasithea Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (26.22) | (24.91) | |
| Return On Tangible Assets | (1.86) | (1.76) | |
| Return On Capital Employed | (0.95) | (1.00) | |
| Return On Assets | (0.87) | (0.82) | |
| Return On Equity | (0.94) | (0.99) |
Things to note about Pasithea Therapeutics performance evaluation
Checking the ongoing alerts about Pasithea Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pasithea Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pasithea Therapeutics generated a negative expected return over the last 90 days | |
| Pasithea Therapeutics has high historical volatility and very poor performance | |
| Pasithea Therapeutics may become a speculative penny stock | |
| Pasithea Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 486.56 K. Net Loss for the year was (13.9 B) with loss before overhead, payroll, taxes, and interest of (2.21 K). | |
| Pasithea Therapeutics Corp currently holds about 47.94 M in cash with (13.92 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pasithea Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference |
- Analyzing Pasithea Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pasithea Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Pasithea Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pasithea Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pasithea Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pasithea Therapeutics' stock. These opinions can provide insight into Pasithea Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pasithea Stock analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |